AU2018338451A1 - Immunoassays for detection of RAN proteins - Google Patents

Immunoassays for detection of RAN proteins Download PDF

Info

Publication number
AU2018338451A1
AU2018338451A1 AU2018338451A AU2018338451A AU2018338451A1 AU 2018338451 A1 AU2018338451 A1 AU 2018338451A1 AU 2018338451 A AU2018338451 A AU 2018338451A AU 2018338451 A AU2018338451 A AU 2018338451A AU 2018338451 A1 AU2018338451 A1 AU 2018338451A1
Authority
AU
Australia
Prior art keywords
ran
poly
subject
antibody
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018338451A
Other languages
English (en)
Inventor
Lien Nguyen
Laura Ranum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of AU2018338451A1 publication Critical patent/AU2018338451A1/en
Priority to AU2024219412A priority Critical patent/AU2024219412A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/30—Electrochemically active labels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2018338451A 2017-09-25 2018-09-25 Immunoassays for detection of RAN proteins Abandoned AU2018338451A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024219412A AU2024219412A1 (en) 2017-09-25 2024-09-04 Immunoassays for detection of ran proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563009P 2017-09-25 2017-09-25
US62/563,009 2017-09-25
PCT/US2018/052745 WO2019060918A1 (en) 2017-09-25 2018-09-25 IMMUNOLOGICAL ASSAYS FOR DETECTION OF RAN PROTEINS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024219412A Division AU2024219412A1 (en) 2017-09-25 2024-09-04 Immunoassays for detection of ran proteins

Publications (1)

Publication Number Publication Date
AU2018338451A1 true AU2018338451A1 (en) 2020-04-02

Family

ID=65811531

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018338451A Abandoned AU2018338451A1 (en) 2017-09-25 2018-09-25 Immunoassays for detection of RAN proteins
AU2024219412A Pending AU2024219412A1 (en) 2017-09-25 2024-09-04 Immunoassays for detection of ran proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024219412A Pending AU2024219412A1 (en) 2017-09-25 2024-09-04 Immunoassays for detection of ran proteins

Country Status (6)

Country Link
US (1) US12504380B2 (enExample)
EP (1) EP3688020A4 (enExample)
JP (2) JP2020535448A (enExample)
AU (2) AU2018338451A1 (enExample)
CA (1) CA3075908A1 (enExample)
WO (1) WO2019060918A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10295547B2 (en) 2013-03-14 2019-05-21 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with ALS
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
EP3612190A4 (en) 2017-04-17 2021-01-20 University of Florida Research Foundation, Incorporated REGULATION OF RAN TRANSLATION THROUGH PKR AND EIF2A-P WAYS
EP3688020A4 (en) 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
AU2018342105B2 (en) 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
WO2021007110A1 (en) * 2019-07-05 2021-01-14 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
AU2020348916B2 (en) * 2019-09-20 2025-12-18 University Of Florida Research Foundation, Incorporated Detection of antibodies against RAN proteins from serum and tissue lysates
WO2021072187A2 (en) * 2019-10-10 2021-04-15 University Of Florida Research Foundation, Incorporated Ran proteins as biomarkers in cag/ctg expansion disorders
WO2023164686A2 (en) * 2022-02-28 2023-08-31 University Of Florida Researchfoundation, Incorporated Ran proteins in sporadic amyotrophic lateral sclerosis

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
CZ321497A3 (cs) 1995-04-11 1998-06-17 Merck And Co., Inc. Způsob vhodný pro produkci látek, jejichž základ tvoří dipeptid
JP2001514508A (ja) 1997-03-05 2001-09-11 ユニバーシティー オブ ワシントン Ｃ型肝炎ウイルスの複製を選択的に抑制する薬剤を同定するための新規なスクリーニング法
JP2002513295A (ja) 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド １２３種類のヒト分泌タンパク質
WO1999011667A1 (en) 1997-08-29 1999-03-11 Innogenetics N.V. METHYLATED, SmD HOMOLOGOUS PEPTIDES, REACTIVE WITH THE ANTIBODIES FROM SERA OF LIVING BEINGS AFFECTED WITH SYSTEMIC LUPUS ERYTHEMATOSUS
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004520803A (ja) 2000-04-21 2004-07-15 コリクサ コーポレイション 尋常性挫瘡の治療および診断のための組成物および方法
WO2002062945A2 (en) 2000-10-25 2002-08-15 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
EP1349934A2 (en) 2000-11-20 2003-10-08 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
US7528227B2 (en) 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7393642B2 (en) 2003-07-17 2008-07-01 Chicago Community Foundation Methods and primers for diagnosing idiopathic congenital central hypoventilation syndrome
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
EP1732598A4 (en) 2003-12-31 2009-08-26 Pharmexa Inc TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
JP4878551B2 (ja) 2004-04-08 2012-02-15 貞和 相磯 運動ニューロン疾患治療薬
EP1794593A2 (en) * 2004-09-21 2007-06-13 Matritech, Inc. Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
CA2596588C (en) 2005-01-31 2017-06-27 University Of Iowa Research Foundation Nucleic acid silencing of huntington's disease gene
WO2006133194A2 (en) 2005-06-06 2006-12-14 Vgx Pharmaceuticals, Inc Methods for treating viral infection with oral or injectible drug solution
CA2629294A1 (en) 2005-11-11 2007-05-24 Aurogen Inc. Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin
WO2008035096A1 (en) * 2006-09-20 2008-03-27 Queen's University Of Belfast Assay
WO2008097861A2 (en) 2007-02-02 2008-08-14 Braincells, Inc. MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
US20090148866A1 (en) * 2007-05-18 2009-06-11 Abbott Laboratories Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase
WO2008151833A2 (en) 2007-06-13 2008-12-18 Hochschule Mannheim Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
US20090143418A1 (en) 2007-11-30 2009-06-04 The Regents Of The University Of Michigan Compositions and Methods for Preventing and Treating Hair Growth Cycle-Related Conditions
GB0809821D0 (en) 2008-05-30 2008-07-09 Univ Aberdeen Treatment and diagnosis of behavioural disorders
TW201034684A (en) 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
WO2010115033A2 (en) 2009-04-02 2010-10-07 Regents Of The University Of Minnesota Nucleotide repeat expansion-associated polypeptides and uses thereof
PT2419144T (pt) 2009-04-17 2019-09-16 Univ Oxford Innovation Ltd Composição para a administração de material genético
WO2010132982A1 (en) 2009-05-18 2010-11-25 Ottawa Hospital Research Institute Treatment of muscle disease characterized by insulin resistance
WO2011028912A2 (en) 2009-09-03 2011-03-10 University Of Tennessee Research Foundation A biomarker for neurodegeneration in neurological disease
KR101133243B1 (ko) 2009-10-29 2012-04-06 국립암센터 암의 진단 및 치료를 위한 ｅＩＦ３ｍ의 용도
WO2011121109A1 (en) 2010-04-02 2011-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
TWI654203B (zh) * 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
WO2013030588A1 (en) 2011-08-31 2013-03-07 The University Of Manchester Method for diagnosing a neurodegenerative disease
CA2853412C (en) 2011-10-28 2021-05-04 University Of Zurich Tdp-43 specific binding molecules
CA2865011C (en) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
KR101417272B1 (ko) 2012-05-15 2014-07-14 경상대학교산학협력단 메트포민 및/또는 타이모퀴논을 포함하는 임신중 알코올 노출에 의한 신경질환 치료 또는 예방용 약학적 조성물
US20140100282A1 (en) 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
RS59283B1 (sr) 2013-01-22 2019-10-31 Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V Proteini sa dipeptidnim ponovkom kao terapeutsko ciljno mesto kod neurodegenerativnih bolesti sa ekspanzijom heksanukleotidnog ponovka
WO2014114303A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
WO2014116865A1 (en) 2013-01-24 2014-07-31 Mayo Foundation For Medical Education And Research Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
US10295547B2 (en) 2013-03-14 2019-05-21 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with ALS
WO2014144952A2 (en) 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
WO2014186746A1 (en) 2013-05-16 2014-11-20 University Of Florida Research Foundation, Inc. HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION
EP2837390A1 (en) 2013-08-15 2015-02-18 Universitäts-Kinderspital beider Basel Combined Pharmaceutical Preparation for Use in Treating Neuromuscular Disorders
CA2990161A1 (en) * 2014-08-13 2016-02-18 The Scripps Research Institute Treatment of c9ftd/als by targeting rna expanded repeat sequences
JP6508996B2 (ja) * 2015-03-24 2019-05-08 東ソー株式会社 β−ＡＮＰによる心不全の検出方法
WO2016168143A1 (en) 2015-04-14 2016-10-20 Bristol-Myers Squibb Company IMMUNOASSAY FOR SOLUBLE PROGRAMMED DEATH-1 (sPD-1) PROTEIN
WO2016191241A1 (en) 2015-05-27 2016-12-01 Mmc & Company Llc Dual target mitochondrial impinging pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
EP3356827B1 (en) * 2015-10-02 2023-12-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides
EP3612190A4 (en) 2017-04-17 2021-01-20 University of Florida Research Foundation, Incorporated REGULATION OF RAN TRANSLATION THROUGH PKR AND EIF2A-P WAYS
EP3688020A4 (en) 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
AU2018342105B2 (en) 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
US11988676B2 (en) 2017-11-16 2024-05-21 Brainbox Solutions, Inc. Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
US20220202935A1 (en) 2019-05-02 2022-06-30 Deutsches Zentrum Für Neurodegenrative Erkrankungen E.V.(Dzne) Immunogen for Preventing or Treating Familial Frontotemporal Dementia (FTD) and/or Amyotrophic Lateral Sclerosis (ALS)
WO2021007110A1 (en) 2019-07-05 2021-01-14 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
AU2020348916B2 (en) 2019-09-20 2025-12-18 University Of Florida Research Foundation, Incorporated Detection of antibodies against RAN proteins from serum and tissue lysates
US20230218730A1 (en) 2019-09-23 2023-07-13 University Of Florida Research Foundation, Incorporated Vaccine therapy for ran protein diseases
WO2021072187A2 (en) 2019-10-10 2021-04-15 University Of Florida Research Foundation, Incorporated Ran proteins as biomarkers in cag/ctg expansion disorders
US20230304088A1 (en) 2020-05-15 2023-09-28 University Of Florida Research Foundation, Incorporated Compositions and methods of detection of pre-symptomatic als
US20250041247A1 (en) 2021-12-01 2025-02-06 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies
WO2023164686A2 (en) 2022-02-28 2023-08-31 University Of Florida Researchfoundation, Incorporated Ran proteins in sporadic amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
CA3075908A1 (en) 2019-03-28
EP3688020A1 (en) 2020-08-05
US12504380B2 (en) 2025-12-23
WO2019060918A1 (en) 2019-03-28
WO2019060918A8 (en) 2019-04-18
AU2024219412A1 (en) 2024-09-26
JP2020535448A (ja) 2020-12-03
JP2023174663A (ja) 2023-12-08
EP3688020A4 (en) 2021-07-14
US20200232925A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
US12504380B2 (en) Immunoassays for detection of ran proteins
US8753892B2 (en) Phosphodiesterase 4D7 as prostate cancer marker
US20240069039A1 (en) Ran proteins as biomarkers in cag/ctg expansion disorders
JP2011501741A (ja) がんの診断および治療のためのｔａｚ／ｗｗｔｒ１
WO2014208645A1 (ja) そう痒を伴う疾患に罹患した患者のｉｌ－３１アンタゴニストによる治療に対する応答を予測する方法
JP2005510251A5 (enExample)
KR20230081950A (ko) 갑상선 안병증의 진단을 위한 바이오마커 및 이의 용도
JP6240919B2 (ja) 加齢または筋萎縮の診断用バイオマーカー
US20160139149A1 (en) Chi3l1 for the detection and treatment of nonalcoholic steatohepatitis
JP2006520588A (ja) 治療薬、予防薬、および診断薬
KR102583540B1 (ko) 퇴행성 뇌질환에서 zbtb16의 용도
CN111630185A (zh) 包含pmvk作为活性成分的用于诊断耐放射癌症或预测放射疗法预后的生物标志物组合物
EP2791686B1 (en) Tenascin-c and use thereof in rheumatoid arthritis
JP2016104716A (ja) 膵臓癌治療用のｃｄ９５シグナル伝達阻害化合物
US20240210407A1 (en) Compositions and methods for detecting and treating pathological fibroblast cells
CN111440870A (zh) CircZCCHC11及其翻译的肽段在肿瘤生长和转移预测、预后评估和治疗中的应用
JP5830329B2 (ja) 腎障害の新規マーカー
US20240280590A1 (en) Compositions and methods for facioscapulohumeral muscular dystrophy biomarker detection
CA2801162A1 (en) Diagnostic, screening and therapeutic applications of ocab-based tools
US7674578B2 (en) Methods of using sIP-10 to assess HCV clearance and/or response to interferon therapy
JP2025077049A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
WO2023041805A1 (en) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
CN117794584A (zh) 包含msh2或msh6抑制剂作为有效成分的用于预防或治疗癌症的组合物
JPWO2006035702A1 (ja) Ｃペプチド特異的結合分子及びその用途
HK1145856B (en) Cd44 splice variants in neurodegenerative diseases

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted